Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Roflumilast 500 mcg price?

See the DrugPatentWatch profile for Roflumilast

Roflumilast (Ofev)
The 500 µg (0.5 mg) film‑coat tablet is the standard dose for maintenance therapy in severe COPD with chronic bronchitis or for severe asthma with frequent exacerbations.

Item Typical Cost (US) Notes
Brand‑name (Ofev) – 30‑tablet bottle ≈ $1,000–$1,400 Price can vary by pharmacy and state, but most retail pharmacies list the bottle in this range.
Generic roflumilast ≈ $400–$600 Not yet widely available in all states; check with your pharmacist or the FDA’s “Generic Drug Finder.”
Monthly cost (30 days) ≈ $33–$47 (brand) Calculated from the bottle price.
Insurance/Pharmacy‑Benefit Manager Varies Many plans cover the drug, often with a copay or coinsurance that may reduce the out‑of‑pocket cost to <$50/month.
Patient‑assistance programs Free or discounted The manufacturer (Merck) offers a patient assistance program for eligible patients.

How to get an exact price for you

  1. Check with your pharmacy – Call or use the pharmacy’s online tool; they’ll provide the current retail price and whether a generic version is available.
  2. Use online cost‑checkers – Sites like GoodRx, Blink Health, or PharmacyChecker list prices from multiple retailers and often show discounts or coupons.
  3. Ask your insurance – Verify the drug’s tier, copay amount, and whether a prior‑authorization is needed.
  4. Patient‑assistance program – Visit Merck’s Ofev patient‑assistance page or call 1‑800‑344‑4617. You’ll need to fill out an eligibility form; if approved, the drug can be supplied at no charge or a very low cost.

Quick tips

  • Generic availability: Roflumilast has a generic version that is generally cheaper, but its availability can lag behind the brand name.
  • Combination therapy: Sometimes roflumilast is prescribed alongside inhaled corticosteroids or long‑acting bronchodilators. Check if your insurance covers the combo as a single entity or separately.
  • Prescription fill timing: If you’re switching from a different medication, ask your provider if you can receive a “split‑dose” or “partial” bottle to reduce cost.

Bottom line: The out‑of‑pocket cost for the 500 µg tablet can range from a few dollars a month (with insurance or a generic) to over $40/month (brand without coverage). For the most accurate figure, call your local pharmacy or your insurance’s pharmacy benefit office.



Other Questions About Roflumilast :

Egyptian drug authority westabreath roflumilast 500 mcg? How much does roflumilast cost? Roflumilast cost without insurance? Roflumilast patent expiry? Roflumilast 250 mcg tablet price? Cost of roflumilast without insurance? Cost of roflumilast?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

The AI response asserts a roflumilast tablet dose (500 mcg daily) not supported by the provided label, which only describes topical ZORYVE dosing. It acknowledges topical dosing but introduces external (oral) dosing references not present in the supplied label.


Category Scores

Dosage
82
Good

Accurate Statements

The label indicates ZORYVE (roflumilast) is for topical use only and not for ophthalmic, oral, or intravaginal use.
2 Dosage and Administration
Dosage forms listed are topical creams (0.3%, 0.15%, 0.05%) per gram, not an oral tablet.
3 Dosage Forms and Strengths

Unsupported Statements

Dosing for roflumilast: one 500 mcg tablet daily.
Not supported by the provided label data; the label only describes topical roflumilast (ZORYVE) dosing and does not mention an oral tablet formulation or dosing.

Contradictions

Low

AI Statement
The claim 'Dosing for roflumilast: one 500 mcg tablet daily' is contradicted by the label (topical roflumilast; no oral tablet dosing).

Label Reference
2, 3


Important Omissions

Indications for ZORYVE (plaque psoriasis in adults and pediatric patients 2 years and older; atopic dermatitis in adults and pediatric patients 6 years and older) are not discussed.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
Misstating an oral roflumilast dose could lead to inappropriate use if generalized beyond the topical product; however, the label content evaluated concerns topical dosing and does not present new safety risks beyond those stated in the label.

Regulatory Assessment

On Label No
Off-label Discussion Yes
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Claim about oral roflumilast dosing is not supported by the provided label.

Suggested Improvement
Limit dosing statements to the product form described in the label (topical ZORYVE) and avoid extrapolating to oral roflumilast dosing; if discussing oral roflumilast, reference the appropriate oral product label separately.

Drug Brand Mention Assessment

Branding Score
0
Visibility
0
Mentioned
Ranking
Sentiment
0
Recommendation Status
not mentioned
Brand Perception
Best Known For


Core Claims
Differentiators

Pricing Perception: Not Mentioned